📜 Post with us on Reddit
📝 Create a new article
🏭 Create a company page
🇬🇧 - in English
🇫🇷 - en Français (FR)
🇵🇹 - em Português (PT)
🇩🇪 - auf Deutsch (DE)
🇯🇵 - 日本語で (JA)
Sponsored articles

You can edit almost every page by Creating an account and confirming your email.

Gilles J Guillemin

From EverybodyWiki Bios & Wiki


Professor Gilles J. Guillemin (born January 1967) is a French-Australian neuroscientist at Macquarie University. He received the Ordre national du Mérite in 2019 in recognition of his work in medical research.[1]

Biography

Dijon, Burgundy, France

Born in Dijon, France in January 1967, Guillemin moved to Australia in 1997 to pursue post-doctoral studies after he obtained a PhD in Neurovirology from the University of Burgundy.[2]

Guillemin has been working in the field of Neuroimmunology since then, with a focus on tryptophan metabolism research.[3]

In 2011, he was involved in the founding of The Motor Neurone Disease (MND) Research Centre at Macquarie University.[4] He was co-director of the centre from 2011 to 2016. As part of his work at the centre, Guillemin and his group study "the involvement of tryptophan in MND" and focus on neuroinflammation and neurotoxicity.[5]

Notable work

Guillemin has been studying the involvement of tryptophan catabolism (via the kynurenine pathway- KP B) in human neurodegenerative diseases for more than 20 years.[6] Guillemin and his teams have conducted research that demonstrates the importance of the KP in multiple sclerosis, Alzheimer's disease and motor neuron disease, which has diagnostic, prognostic and therapeutic potential.[7] [8] This research has been extended to looking at the chemicals in the brain and their relation to other diseases such as depression, suicide, autism and cancers.[9][10]


Guillemin is part of a research group working on neuroactive (toxic or protective) metabolites derived from tryptophan.[11]

As a result of their research, the team has identified a " new process for the uptake of the neurotoxin quinolinic acid (QUIN) in human neurons that could reduce the impact of major inflammatory diseases". [12] The study built on the results of previous research by Guillemin that demonstrated excessive amounts of QUIN accumulate within the human brain of Alzheimer’s and motor neuron disease (MND) patients.[13]


As an extension of his research on tryptophan and QUIN, Guillemin has also conducted research into Multiple Sclerosis (MS), including a project that discovered the first blood biomarker for MS. [14][15] The result of the project was the identification of a biomarker that can discriminate between the three subtypes of MS with 85-90 percent accuracy, allowing for a more accurate diagnosis of MS in patients. [16][17][18]

Motor Neurone Disease BioBank

In 2012, Guillemin, with his colleague Dominic Rowe, co-created the first MND biobank in Australia.[19]

The Motor Neurone Disease (MND) Biobank houses samples that are then available to for use in research projects. One such project was conducted by Guillemin and his team around the analysis of the blood plasma of Amyotrophic lateral sclerosis patients to find ways to improve diagnosis. [20]

Pandis

In 2018, Guillemin co-created PANDIS with Catherine Stace.[21] PANDIS is an Australian not-for-profit organisation.[22]

The aim of the organisation is to indentify “infectious pathogens in Australian patients with various types of chronic diseases”, called PAN diseases, or PANDAS, with a focus on tick-borne diseases. PANDIS is due to launch a "tick tracker" in late 2020 as part of a community science program.[23]

Community engagement

Guillemin is involved in "Scientists in Schools" a CSIRO Education program where he shares his experience as a scientist to primary and secondary school students.[24]

Publications

Guillemin has had work published in various Scientific Journals including; New England Journal of Medicine[25] and Nature.[26][27]

Guillemin has been the Editor-in-Chief of The International Journal on Tryptophan Research since 2008.[28] He is a member of the Editorial Board for Neurotoxicity Research.[29] He is also a member and editor for Journal of Alzheimer’s disease.[30]

Professional memberships

  • 2014 - 2020: Elected President of the International Society of Tryptophan research (ISTRY)[31]
  • 2018 - Present: Scientific advisor for Implicit Biosciences[32]
  • 2014 - Present: Acting CSO for Metabrain Research(France) since June 2014[33]
  • 2012 - 2016: Elected President of the International Neurotoxicity Society (NTS)[34]
  • 2003-2012: Member of the executive committee of the International Neurotoxicity Society (NTS)[34]
  • Since 2009: Member of the executive committee of the International Society of Tryptophan research (ISTRY)[35]

Awards and honours

  • 2020, March: Awarded a Fellowship of The Royal Society of New South Wales.[36][37]
  • 2019, November: Awarded “Chevalier (Knight) de l’Ordre du Mérite” by the French government in recognition of his work in medical research[38]
  • 2017: Finalist for the Eureka prize (best Australian Medical discovery of the year)[39]
  • 2012: Made a member of the ‘Century Club’ at UNSW recognising his 100th publication achievement[40]

References

  1. ↑ "The National Order of Merit | La grande chancellerie". www.legiondhonneur.fr. Archived from the original on 2024-01-20. Retrieved 2020-12-04.
  2. ↑ "60 seconds with… Professor Gilles Guillemin | This Week At Macquarie University". Retrieved 2020-08-03.
  3. ↑ Administration. "Our projects". Macquarie University. Archived from the original on 2019-03-30. Retrieved 2020-08-03.
  4. ↑ Administration. "Macquarie University Centre for Motor Neuron Disease Research". Macquarie University. Retrieved 2020-08-03.
  5. ↑ Administration. "Guillemin Group". Macquarie University. Retrieved 2020-12-04.
  6. ↑ Adams, Seray; Teo, Charles; McDonald, Kerrie L.; Zinger, Anna; Bustamante, Sonia; Lim, Chai K.; Sundaram, Gayathri; Braidy, Nady; Brew, Bruce J.; Guillemin, Gilles J. (2014). "Involvement of the kynurenine pathway in human glioma pathophysiology". PLOS ONE. 9 (11): e112945. Bibcode:2014PLoSO...9k2945A. doi:10.1371/journal.pone.0112945. ISSN 1932-6203. PMC 4240539. PMID 25415278.
  7. ↑ "Involvement of the kynurenine pathway in MS". MS Research Australia. Retrieved 2020-12-20.
  8. ↑ "New mechanisms to reduce impact of neuroinflammatory diseases". UNSW Sydney Medicine. Retrieved 20/12/2020. Unknown parameter |url-status= ignored (help); Check date values in: |access-date= (help)
  9. ↑ 2016 - 3:10PMnews.com.au (2016-08-02). "Breakthrough in suicide prevention". dailytelegraph. Retrieved 2020-12-20.
  10. ↑ "Inflammation linked to chemical imbalance in schizophrenia". medicalxpress.com. Retrieved 2020-12-20.
  11. ↑ Administration. "Guillemin Group". Macquarie University. Retrieved 2020-08-03.
  12. ↑ SCIMEX (1599525000). "New mechanisms to reduce impact of neuroinflammatory diseases". Scimex. Retrieved 2020-12-20. Check date values in: |date= (help)
  13. ↑ "New Mechanisms to Reduce Impact of Neuroinflammatory Diseases". Medianet. Retrieved 2020-12-20.
  14. ↑ "Blood biomarker discovery a breakthrough for MS sufferers | Keep It Clever". keepitclever.com.au. Retrieved 2020-12-20.
  15. ↑ "MS research breakthrough". MSWA. Retrieved 2020-12-20.
  16. ↑ "First blood biomarker discovered for the prognosis of multiple sclerosis: quick, accurate and soon to be available". Archived from the original on 2017-09-15. Retrieved 2020-12-20.
  17. ↑ "'Stunning breakthrough' helping to rapidly identify types of MS". www.abc.net.au. 2017-02-03. Retrieved 2020-12-20.
  18. ↑ "Blood Test for Multiple Sclerosis May Be Near". HCPLive. Retrieved 2020-12-20.
  19. ↑ "Gilles Guillemin". Macquarie University. Retrieved 2020-08-03.
  20. ↑ "Researchers conduct metabolite analysis of ALS patient blood plasma". medicalxpress.com. Retrieved 2020-12-20.
  21. ↑ "PANDIS (microorganisms & human diseases - Tick-born diseases)". Macquarie University. Archived from the original on 2020-09-19. Retrieved 2020-08-13.
  22. ↑ "Personalized Medicine Model Aiming To Improve Diagnosis and Treatment of Chronic Diseases". Diagnostics from Technology Networks. Retrieved 2020-12-20.
  23. ↑ Admin, Pandis (2020-10-11). "MS Research". PANDIS. Retrieved 2020-12-20.
  24. ↑ CSIRO. "STEM Professionals in Schools". www.csiro.au. Retrieved 2020-08-03.
  25. ↑ Shi, Hongjun; Enriquez, Annabelle; Rapadas, Melissa; Martin, Ella M.M.A.; Wang, Roni; Moreau, Julie; Lim, Chai K.; Szot, Justin O.; Ip, Eddie; Hughes, James N.; Sugimoto, Kotaro (2017-08-10). "NAD Deficiency, Congenital Malformations, and Niacin Supplementation". New England Journal of Medicine. 377 (6): 544–552. doi:10.1056/NEJMoa1616361. ISSN 0028-4793. PMID 28792876. Unknown parameter |s2cid= ignored (help)
  26. ↑ Lim, Chai K.; Bilgin, Ayse; Lovejoy, David B.; Tan, Vanessa; Bustamante, Sonia; Taylor, Bruce V.; Bessede, Alban; Brew, Bruce J.; Guillemin, Gilles J. (2017-02-03). "Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression". Scientific Reports. 7 (1): 41473. Bibcode:2017NatSR...741473L. doi:10.1038/srep41473. ISSN 2045-2322. PMC 5290739. PMID 28155867.
  27. ↑ Chatterjee, Pratishtha; Goozee, Kathryn; Lim, Chai K.; James, Ian; Shen, Kaikai; Jacobs, Kelly R.; Sohrabi, Hamid R.; Shah, Tejal; Asih, Prita R.; Dave, Preeti; ManYan, Candice (2018-05-22). "Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-β load: A pilot study". Scientific Reports. 8 (1): 8008. Bibcode:2018NatSR...8.8008C. doi:10.1038/s41598-018-25968-7. ISSN 2045-2322. PMC 5964182. PMID 29789640.
  28. ↑ "International Journal of Tryptophan Research". SAGE Journals. Retrieved 2020-08-03.
  29. ↑ "Neurotoxicity Research". Springer. Retrieved 2020-08-03.
  30. ↑ "Members Directory | Journal of Alzheimer's Disease". www.j-alz.com. Retrieved 2020-08-03.
  31. ↑ "Executive Committee | ISTRY". www.istry.org. Retrieved 2020-08-03.
  32. ↑ "The Team – Implicit Bioscience Limited". Retrieved 2020-12-04.
  33. ↑ "METABRAIN". www.metabrainresearch.com. Retrieved 2020-08-03.
  34. ↑ 34.0 34.1 "Our Officers and Council". www.neurotoxicitysociety.org. Retrieved 2020-12-04.
  35. ↑ "Executive Committee | ISTRY". www.istry.org. Retrieved 2020-12-04.
  36. ↑ "Fellows - The Royal Society of NSW". royalsoc.org.au. Retrieved 2020-08-03.
  37. ↑ "Home - The Royal Society of NSW". royalsoc.org.au. Retrieved 2020-12-20.
  38. ↑ "The National Order of Merit | La grande chancellerie". www.legiondhonneur.fr. Archived from the original on 2024-01-20. Retrieved 2020-08-03.
  39. ↑ "2017 Australian Museum Eureka Awards". MS Research Australia. Retrieved 2020-08-03.
  40. ↑ "SOMS Century Club". Unknown parameter |url-status= ignored (help)

Further reading

Published articles

1. Herpetosiphon Secondary Metabolites Inhibit Amyloid-β Toxicity in Human Primary Astrocytes. Dehhaghi M, Kazemi Shariat Panahi H, Braidy N, Guillemin GJ. J Alzheimers Dis. 2020 May 26. doi: 10.3233/JAD-200116. Online ahead of print.PMID: 32474470

2. Metabolite Profiling Reveals Predictive Biomarkers and the Absence of β-Methyl Amino-l-alanine in Plasma from Individuals Diagnosed with Amyotrophic Lateral Sclerosis. Bereman MS, Kirkwood KI, Sabaretnam T, Furlong S, Rowe DB, Guillemin GJ, Mellinger AL, Muddiman DC. J Proteome Res. 2020 Jun 2. doi: 10.1021/acs.jproteome.0c00216. Online ahead of print.PMID: 32418425

3. Autism and Gut-Brain Axis: Role of Probiotics. Chidambaram SB, Tuladhar S, Bhat A, Mahalakshmi AM, Ray B, Essa MM, Bishir M, Bolla SR, Nanjaiah ND, Guillemin GJ, Qoronfleh MW. Adv Neurobiol. 2020;24:587-600. doi: 10.1007/978-3-030-30402-7_21.PMID: 32006375 Review.

4. Protein Nutrition in Autism. Chidambaram SB, Bhat A, Mahalakshmi AM, Ray B, Tuladhar S, Sushmitha BS, Saravanan B, Thamilarasan M, Thenmozhi AJ, Essa MM, Guillemin GJ, Qoronfleh MW. Adv Neurobiol. 2020;24:573-586. doi: 10.1007/978-3-030-30402-7_20.PMID: 32006374 Review.

5. Inflammation and kynurenine pathway dysregulation in post-partum women with severe and suicidal depression. Achtyes E, Keaton SA, Smart L, Burmeister AR, Heilman PL, Krzyzanowski S, Nagalla M, Guillemin GJ, Escobar Galvis ML, Lim CK, Muzik M, Postolache TT, Leach R, Brundin L. Brain Behav Immun. 2020 Jan;83:239-247. doi: 10.1016/j.bbi.2019.10.017. Epub 2019 Nov 5.

6. Inflammation and kynurenine pathway dysregulation in post-partum women with severe and suicidal depression. Achtyes E, Keaton SA, Smart L, Burmeister AR, Heilman PL, Krzyzanowski S, Nagalla M, Guillemin GJ, Escobar Galvis ML, Lim CK, Muzik M, Postolache TT, Leach R, Brundin L. Brain Behav Immun. 2020 Jan;83:239-247. doi: 10.1016/j.bbi.2019.10.017. Epub 2019 Nov 5.

7. Kynurenine Pathway Metabolites as Biomarkers for Amyotrophic Lateral Sclerosis. Tan VX, Guillemin GJ. Front Neurosci. 2019 Sep 20;13:1013. doi: 10.3389/fnins.2019.01013. eCollection 2019. Review.

8. The Cyanotoxin and Non-protein Amino Acid β-Methylamino-L-Alanine (L-BMAA) in the Food Chain: Incorporation into Proteins and Its Impact on Human Health. Dunlop RA, Guillemin GJ. Neurotox Res. 2019 Oct;36(3):602-611. doi: 10.1007/s12640-019-00089-9. Epub 2019 Aug 3. Review.

9. Microbiota Alterations in Alzheimer's Disease: Involvement of the Kynurenine Pathway and Inflammation. Garcez ML, Jacobs KR, Guillemin GJ. Neurotox Res. 2019 May 14. doi: 10.1007/s12640-019-00057-3. Review.

10. Fungal-contaminated grass and well water and sporadic amyotrophic lateral sclerosis. French PW, Ludowyke RI, Guillemin GJ. Neural Regen Res. 2019 Sep;14(9):1490-1493. doi: 10.4103/1673-5374.255959. Review.

11. Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau. Jacobs KR, Lim CK, Blennow K, Zetterberg H, Chatterjee P, Martins RN, Brew BJ, Guillemin GJ*, Lovejoy DB*. Neurobiol Aging. 2019 Apr 1;80:11-20. doi: 10.1016/j.neurobiolaging.2019.03.015. (*Co-senior author)

12. Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. Kindler J, Lim CK, Weickert CS, Boerrigter D, Galletly C, Liu D, Jacobs KR, Balzan R, Bruggemann J, O'Donnell M, Lenroot R, Guillemin GJ*, Weickert TW*. Mol Psychiatry. 2019 Apr 3. doi: 10.1038/s41380-019-0401-9. (*Co-senior author)

13.Human Tick-Borne Diseases in Australia. Dehhaghi M, Kazemi Shariat Panahi H, Holmes EC, Hudson BJ, Schloeffel R, Guillemin GJ. Front Cell Infect Microbiol. 2019 Jan 28;9:3. doi: 10.3389/fcimb.2019.00003. eCollection 2019. Review.

14. Protective Effects of Antioxidants in Huntington's Disease: an Extensive Review. Essa MM, Moghadas M, Ba-Omar T, Walid Qoronfleh M, Guillemin GJ, Manivasagam T, Justin-Thenmozhi A, Ray B, Bhat A, Chidambaram SB, Fernandes AJ, Song BJ, Akbar M. Neurotox Res. 2019 Jan 11. [Epub ahead of print] Review.

15. Dendritic spines: Revisiting the physiological role. Chidambaram SB, Rathipriya AG, Bolla SR, Bhat A, Ray B, Mahalakshmi AM, Manivasagam T, Thenmozhi AJ, Essa MM, Guillemin GJ, Chandra R, Sakharkar MK. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jan 15;92:161-193. [Epub ahead of print] Review

16. Time-dependent effect of oligomeric amyloid-β (1-42)-induced hippocampal neurodegeneration in rat model of Alzheimer's disease. Karthick C, Nithiyanandan S, Essa MM, Guillemin GJ, Jayachandran SK, Anusuyadevi M. Neurol Res. 2019 Feb;41(2):139-150. Epub 2018 Nov 19.

17. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms. Castellano-Gonzalez G, Jacobs KR, Don E, Cole NJ, Adams S, Lim CK, Lovejoy DB, Guillemin GJ. Neurotox Res. 2019 Jan 21 doi: 10.1007/s12640-019-9997-4. [Epub ahead of print]

18. Neuroprotective Effect of Myxobacterial Extracts on Quinolinic Acid-Induced Toxicity in Primary Human Neurons. Dehhaghi M, Tan V, Heng B, Braidy N, Mohammadipanah F, Guillemin GJ. Neurotox Res. 2019 Feb;35(2):281-290. Epub 2018 Sep 28.

19. Involvement of the kynurenine pathway in human glioma pathophysiology. Adams S, Teo C, McDonald KL, Zinger A, Bustamante S, Lim CK, Sundaram G, Braidy N, Brew BJ, Guillemin GJ. PLoS One. 2014 Nov 21;9(11):e112945. doi: 10.1371/journal.pone.0112945. eCollection 2014.

20. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Zu Schwabedissen LM, Bogerts B, Myint AM. J Neuroinflammation. 2013 Mar 2;10:34. (IF: 4.4)

21. Increased Markers of Oxidative Stress in Autistic Children of the Sultanate of Oman. Essa MM, Guillemin GJ, Waly MI, Al-Sharbati MM, Al-Farsi YM, Hakkim FL, Ali A, Al-Shafaee MS. Biol Trace Elem Res. 2011 Nov 30. [Epub ahead of print] (IF 1.52)

In the media


This article "Gilles J Guillemin" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Gilles J Guillemin. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.


Retrieved from "https://en.everybodywiki.com/index.php?title=Gilles_J_Guillemin&oldid=6330388"
License CC BY-SA 3.0
Powered by MediaWiki